Paraoxonase 1 Q192R variant and clopidogrel efficacy: fact or fiction?
作者信息
Lewis Joshua P, Shuldiner Alan R
出版信息
Circ Cardiovasc Genet. 2012 Apr 1;5(2):153-5. doi: 10.1161/CIRCGENETICS.112.962910.
Abstract
摘要
相似文献
1
Paraoxonase 1 Q192R variant and clopidogrel efficacy: fact or fiction?对氧磷酶1 Q192R变体与氯吡格雷疗效：事实还是虚构？
Circ Cardiovasc Genet. 2012 Apr 1;5(2):153-5. doi: 10.1161/CIRCGENETICS.112.962910.
2
Effect of PON1 Q192R genetic polymorphism on clopidogrel efficacy and cardiovascular events in the Clopidogrel in the Unstable Angina to Prevent Recurrent Events trial and the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events.在“氯吡格雷用于不稳定型心绞痛预防再发事件试验”及“氯吡格雷与厄贝沙坦用于预防血管事件的房颤试验”中，对氧磷酶1（PON1）Q192R基因多态性对氯吡格雷疗效及心血管事件的影响。
Circ Cardiovasc Genet. 2012 Apr 1;5(2):250-6. doi: 10.1161/CIRCGENETICS.111.961417. Epub 2012 Feb 24.
3
PON1 Q192R genotype influences clopidogrel responsiveness by relative platelet inhibition instead of on-treatment platelet reactivity.PON1 Q192R 基因型通过相对血小板抑制而不是治疗中的血小板反应性来影响氯吡格雷反应性。
Thromb Res. 2013 Oct;132(4):444-9. doi: 10.1016/j.thromres.2013.08.004. Epub 2013 Aug 9.
4
Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis.载脂蛋白酯酶 1 Q192R 基因变异对氯吡格雷反应性和复发性心血管事件的影响：系统评价和荟萃分析。
J Thromb Haemost. 2012 Jul;10(7):1242-51. doi: 10.1111/j.1538-7836.2012.04756.x.
5
No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.氯吡格雷治疗血小板反应与支架血栓形成风险与对氧磷酶 1 Q192R 基因型无关。
Eur Heart J. 2011 Jul;32(13):1605-13. doi: 10.1093/eurheartj/ehr155. Epub 2011 Apr 28.
6
Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement.对氧磷酶-1 Q192R多态性与氯吡格雷在择期冠状动脉支架置入患者中的抗血小板作用
Circ Cardiovasc Genet. 2011 Aug 1;4(4):429-36. doi: 10.1161/CIRCGENETICS.111.960112. Epub 2011 Jun 17.
7
Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response.对氧磷酶 1（PON1）基因变异与氯吡格雷反应无关。
Clin Pharmacol Ther. 2011 Oct;90(4):568-74. doi: 10.1038/clpt.2011.194. Epub 2011 Aug 31.
8
Paraoxonase-1 is a major determinant of clopidogrel efficacy.对氧磷酶 1 是氯吡格雷疗效的主要决定因素。
Nat Med. 2011 Jan;17(1):110-6. doi: 10.1038/nm.2281. Epub 2010 Dec 19.
9
[Relevance of CYP2C19 2 regarding platelet reactivity in patients with acute coronary syndrome treated with clopidogrel].[CYP2C19 2对接受氯吡格雷治疗的急性冠状动脉综合征患者血小板反应性的相关性]
Med Clin (Barc). 2014 Jul 7;143(1):6-12. doi: 10.1016/j.medcli.2013.04.042. Epub 2013 Jul 10.
10
Positive clinical response to clopidogrel is independent of paraoxonase 1 Q192R and CYP2C19 genetic variants.氯吡格雷的阳性临床反应独立于对氧磷酶1 Q192R和CYP2C19基因变异。
J Clin Pharmacol. 2014 Aug;54(8):843-9. doi: 10.1002/jcph.275. Epub 2014 Feb 14.
引用本文的文献
1
The role of genotyping to guide antiplatelet therapy following ischemic stroke or transient ischemic attack.基因分型在缺血性卒中和短暂性脑缺血发作后指导抗血小板治疗中的作用。
Expert Rev Clin Pharmacol. 2022 Jul;15(7):811-825. doi: 10.1080/17512433.2022.2108401. Epub 2022 Aug 4.
2
Impact of genetic polymorphisms on platelet function and response to anti platelet drugs.基因多态性对血小板功能及抗血小板药物反应的影响
Cardiovasc Diagn Ther. 2018 Oct;8(5):610-620. doi: 10.21037/cdt.2018.05.06.
3
The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics.氯吡格雷抗血小板治疗的个体化：整合药物遗传学和药物代谢组学的作用。
Cardiol Res Pract. 2017;2017:8062796. doi: 10.1155/2017/8062796. Epub 2017 Mar 21.
4
Both PON1 Q192R and CYP2C19*2 influence platelet response to clopidogrel and ischemic events in Chinese patients undergoing percutaneous coronary intervention.在中国接受经皮冠状动脉介入治疗的患者中，PON1 Q192R和CYP2C19*2均会影响血小板对氯吡格雷的反应及缺血事件。
Int J Clin Exp Med. 2015 Jun 15;8(6):9266-74. eCollection 2015.
5
Pharmacogenomics of anti-platelet and anti-coagulation therapy.抗血小板和抗凝治疗的药物基因组学。
Curr Cardiol Rep. 2013 Jul;15(7):381. doi: 10.1007/s11886-013-0381-3.
6
Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation?抗血小板治疗的药物基因组学：临床实施需要多少证据？
J Hum Genet. 2013 Jun;58(6):339-45. doi: 10.1038/jhg.2013.41. Epub 2013 May 23.
7
A review of pharmacogenetics of adverse drug reactions in elderly people.老年人药物不良反应的药物遗传学研究综述。
Drug Saf. 2012 Jan;35 Suppl 1:3-20. doi: 10.1007/BF03319099.
本文引用的文献
1
Effect of PON1 Q192R genetic polymorphism on clopidogrel efficacy and cardiovascular events in the Clopidogrel in the Unstable Angina to Prevent Recurrent Events trial and the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events.在“氯吡格雷用于不稳定型心绞痛预防再发事件试验”及“氯吡格雷与厄贝沙坦用于预防血管事件的房颤试验”中，对氧磷酶1（PON1）Q192R基因多态性对氯吡格雷疗效及心血管事件的影响。
Circ Cardiovasc Genet. 2012 Apr 1;5(2):250-6. doi: 10.1161/CIRCGENETICS.111.961417. Epub 2012 Feb 24.
2
Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockade.与根据血小板反应性监测调整氯吡格雷剂量以优化 P2Y12-ADP 受体抑制失败相关的因素。
Thromb Res. 2012 Jul;130(1):70-4. doi: 10.1016/j.thromres.2011.12.038. Epub 2012 Jan 27.
3
Predicting clopidogrel response using DNA samples linked to an electronic health record.利用与电子健康记录相关联的 DNA 样本预测氯吡格雷反应。
Clin Pharmacol Ther. 2012 Feb;91(2):257-63. doi: 10.1038/clpt.2011.221. Epub 2011 Dec 21.
4
CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients.CYP2C19 而非 PON1 基因变异影响心肌梗死后患者氯吡格雷的药代动力学、药效学和临床疗效。
Circ Cardiovasc Interv. 2011 Oct 1;4(5):422-8. doi: 10.1161/CIRCINTERVENTIONS.111.963025. Epub 2011 Oct 4.
5
Effect of paraoxonase-1 polymorphism on clinical outcomes in patients treated with clopidogrel after an acute myocardial infarction.对急性心肌梗死后接受氯吡格雷治疗的患者，对氧磷酶-1 多态性对临床结局的影响。
Clin Pharmacol Ther. 2011 Oct;90(4):561-7. doi: 10.1038/clpt.2011.193. Epub 2011 Sep 14.
6
Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response.对氧磷酶 1（PON1）基因变异与氯吡格雷反应无关。
Clin Pharmacol Ther. 2011 Oct;90(4):568-74. doi: 10.1038/clpt.2011.194. Epub 2011 Aug 31.
7
Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study.ADRIE研究中对氧磷酶-1活性、其Q192R基因变异与氯吡格雷反应性之间的关系
J Thromb Haemost. 2011 Aug;9(8):1664-6. doi: 10.1111/j.1538-7836.2011.04409.x.
8
Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement.对氧磷酶-1 Q192R多态性与氯吡格雷在择期冠状动脉支架置入患者中的抗血小板作用
Circ Cardiovasc Genet. 2011 Aug 1;4(4):429-36. doi: 10.1161/CIRCGENETICS.111.960112. Epub 2011 Jun 17.
9
Pharmacogenomics of clopidogrel: evidence and perspectives.氯吡格雷的药物基因组学：证据与展望。
Thromb Res. 2011 Oct;128(4):307-16. doi: 10.1016/j.thromres.2011.04.010. Epub 2011 May 18.
10
No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.氯吡格雷治疗血小板反应与支架血栓形成风险与对氧磷酶 1 Q192R 基因型无关。
Eur Heart J. 2011 Jul;32(13):1605-13. doi: 10.1093/eurheartj/ehr155. Epub 2011 Apr 28.
Zotero 插件